ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB Press release LEIDEN, the Netherlands, April 30, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 30, 2018
ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO Press release Key Updates April 23, 2018
ProQR Announces Annual Meeting of Shareholders Press release LEIDEN, the Netherlands, April 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 11, 2018
ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology Press release Key Updates April 10, 2018
ProQR to Present at Two Upcoming Conferences Press release LEIDEN, the Netherlands, April 03, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 03, 2018
ProQR to Present at Upcoming Investor Conference Press release LEIDEN, the Netherlands, March 05, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. March 05, 2018
ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update Press release Key updates February 28, 2018
ProQR Supports Rare Disease Day 2018 and Honors Henri A. Termeer Press release LEIDEN, the Netherlands, Feb. 27, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. February 27, 2018
Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A Press release Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene. February 12, 2018
ProQR to Present at Upcoming Scientific Meeting and Investor Conference Press release LEIDEN, the Netherlands, Feb. 06, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. February 06, 2018